Athyrium Capital Management, LP

Add to watchlist

$267 Million is the total value of Athyrium Capital Management, LP's 11 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 50.0% .

All

			Value		Shares		↓ Weighting
OSMT	Buy	RVL PHARMACEUTICALS PLC	$30,661,000	+176.7%	14,600,444	+79.2%	11.48%	+146.4%
	Buy	Omeros Corpnote 5.250% 2/1	$22,336,000	+10.1%	40,150,000	+14.2%	8.36%	-2.0%
	New	Paratek Pharmaceuticals Inc.note 4.750% 5/0	$8,000,000	–	9,000,000	+100.0%	3.00%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2022-11-14

Signatures

The EDGAR filing(s) were signed by:

Andrew Hyman — Chief Operating Officer and General Counsel

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
Amryt Pharma PLC	10	Q1 2023	46.3%
Progenity Inc.	9	Q4 2022	69.2%
Progenity Inc.	8	Q3 2023	39.2%
RVL PHARMACEUTICALS PLC	8	Q3 2023	11.5%
Societal CDMO Inc.	8	Q4 2022	3.1%
Omeros Corp	7	Q3 2023	39.3%
CAREMAX INC	7	Q4 2022	27.5%
Omeros Corp	7	Q3 2023	9.9%
PUMA BIOTECHNOLOGY INC	7	Q3 2023	4.2%
AEGERION PHARMACEUTICALS INC	6	Q1 2019	88.7%

View Athyrium Capital Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)

Athyrium Capital Management, LP Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
PROGENITY, INC.	August 27, 2021	4,211,977	2.7%

View Athyrium Capital Management, LP's complete significant-ownership history.

Latest filings

Type	Filed
13F-HR	2024-05-16
13F-HR	2024-02-14
13F-HR	2023-11-14
13F-HR	2023-08-14
13F-HR/A	2023-05-16
13F-HR	2023-05-15
13F-HR	2023-02-14
13F-HR	2022-11-14
13F-HR	2022-08-15
13F-HR	2022-05-16

View Athyrium Capital Management, LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Athyrium Capital Management, LP's holdings